Accelerating Multispecific Biologics: Overcoming Light Chain Mispairing And Manufacturing Bottlenecks With The Lock-In™ Platform

Bispecific and multispecific formats keep gaining ground, yet manufacturing inefficiencies, poor bioavailability, and unintended biological effects still stand between complex designs and viable therapeutics. Light chain mispairing is a major bottleneck in discovery, and the usual fix, reengineering binders around a common light chain, can derail or severely delay a program. Gavin Barnard, PhD, Chief Scientific Officer at ATUM, presents the Lock-In™ platform, a protein engineering approach that eliminates the need for a common light chain while maintaining the structural and biophysical attributes of native IgGs.

See how it optimizes therapeutic leads and accelerates the timeline from discovery to stable CHO cell line development.